Introduction {#s1}
============

Esophageal cancer is the eighth most common cancer worldwide and the sixth most common cause of death of all cancers, over 80% of which occur in less developed regions ([@b1]). In China, the incidence and mortality of esophageal cancer are 14.73/100, 000 and 10.62/100, 000 respectively in 2012, with incidence rates about twofold higher than that in the world ([@b2]). Esophageal cancer has a poor survival since patients in early stages are asymptomatic and usually diagnosed at the advanced stage ([@b3]). Screening, therefore, is the key for detecting patients before they are advanced.

Several screening methods have been launched in high-risk areas of China since 1970s, including conventional cytology ([@b4]-[@b7]), liquid-based cytology ([@b8]), occult blood detection ([@b9]) and endoscopic biopsy examination with Lugol's iodine staining ([@b10]-[@b13]). At present, endoscopic biopsy examination with Lugol's iodine staining, being most commonly conducted in China due to high sensitivity (SE) and specificity (SP), has been proved to significantly reduce accumulative incidence and mortality in high risk areas by a ten-year follow-up study ([@b12]). However, high expenditure and skilled pathologists and endoscopic physicians are required, which makes endoscopic screening not appropriate in the whole population ([@b14], [@b15]). As a result, some convenient and economical primary screening approaches are needed before performing endoscopic examination.

DNA image cytometry (DNA-ICM) has been applied as a mass screening method to cervical cancer and is shown to obtain a higher SE than cytology ([@b16]). To our knowledge, there are limited studies on DNA-ICM for large-scale esophageal cancer screening. Our research team has tried to explore the DNA-ICM in a population-based study of 582 subjects in Linzhou and Feicheng and proved that this technique has the potential to be a primary screening method ([@b17]). On the basis of previous research, we enlarge the population to further evaluate the feasibility of DNA-ICM as a primary screening method for esophageal cancer and determine the cutoff point for esophageal cancer diagnosis.

Materials and methods {#s2}
=====================

Study design and subjects recruitment {#s2-1}
-------------------------------------

This was a population-based screening study, with 5, 382 subjects from three high-risk areas in China (Linzhou in Henan province, Feicheng in Shandong province and Cixian in Hebei province) from 2008 to 2011. Inclusion criteria were: 1) local residents; 2) aged 40-69 years; 3) no contraindications for endoscopic examinations (e.g. history of reaction to iodine or lidocaine, serious cardiovascular disease, poor health status); and 4) voluntarily consenting to participate in screening and signing the informed consent document. Exclusion criteria were: participants who had a history of liver cirrhosis, esophageal varices, hematemesis, a bleeding disorder, uncontrolled congestive heart failure, unstable angina or a reaction to topical anesthetics or iodine. This study was approved by the Institutional Review Boards of the Cancer Institute/Hospital of the Chinese Academy of Medical Sciences (CICAMS) and Peking Union Medical College. The details of subject recruitment and exclusion and the study procedure are described in our previous study ([@b12]).

Endoscopic screening and cytological test sample collection {#s2-2}
-----------------------------------------------------------

Endoscopic screening was completed by local doctors after training and under the supervision of experienced doctors from the CICAMS. The technical processes of endoscopic screening and the requirements of follow-up after screening have been described at length in our former research ([@b17]). The biopsy slides were read blindly by two experienced pathologists without knowledge of the visual endoscopic results. The pathologic results were classed as normal, basal cell hyperplasia (BCH), low grade intraepithelial neoplasia (LGIN), high grade intraepithelial neoplasia (HGIN) and esophageal squamous cell cancer (ESCC).

Balloon examination was performed by an experienced local doctor to collect cytological samples. Then each sample was divided into two slides and stained randomly by a Pap smear or Feulgen method respectively. The former was used for liquid-based cytological study and the latter was employed to DNA-ICM test. The detailed procedures of sample collection, specimens' preparation were in our previous study ([@b17]). The cytological slides were reviewed by two cytopathologists independently, and discrepancies were adjudicated by joint review. The slides were read blindly without the pathological results. The diagnostic criteria for cytological study were normal, benign reactive cellular changes (BCC), atypical squamous cells of undetermined significance (ASCUS), low grade squamous intraepithelial lesion (LISL), high grade squamous intraepithelial lesion (HISL) and ESCC.

The DNA-ICM specimens were read by hard ware systems, including a MOTIC BA600 microscope, DELL370 workstation, automated microscope control-box, Moticam 1501 camera and assistant accessories. Our preceding study had amply depicted the operation principles of the system and the conventional result expression method by the content of DNA ploidy and the number of aneuploidy cells ([@b17]). Based on the former method, we gave every subject who had DNA-ICM test a 4-digit code, which combined the content of DNA ploidy and the number of aneuploidy cells together, and which represented the health condition of each subject. The first two digits meant the maximum DNA ploidy content and the rest two digits accounted for the number of the maximum DNA ploidy content cells. For example, if the maximum DNA ploidy content was 7.5c and the amount of this kind of cell was 22, the 4-digit number was 7, 522. The larger the 4-digit code, the more serious the subject's DNA-ICM result.

Statistical analysis {#s2-3}
--------------------

Analyses were done using SAS 9.2 software (SAS Institute Inc., Cary, NC, USA). Demographic, pathologic and cytological outcomes were compared by χ^2^ test. The correlation between DNA-ICM results and esophageal cancer and precancerous lesions is evaluated by trend test. SE, SP, positive predictive value (PPV) and negative predictive value (NPV), as well as 95% confidence intervals (95% CI) were calculated to indicate the screening ability of DNA-ICM, cytology and the combination of the two methods. Receiver operating characteristic (ROC) curves were applied to determine the cutoff point of DNA-ICM for esophageal cancer, where lay the maximum Youden's index. The statistical significance was accepted at P\<0.05.

Results {#s3}
=======

Demographic characteristics {#s3-1}
---------------------------

A total of 5, 382 local residents aged 40-69 years from Linzhou in Henan province, Cixian in Hebei province and Feicheng in Shandong province were enrolled in the study. The mean age of all participants was 52.7 years (range, 40-69 years) and females accounted for 61% (*[Table 1](#Table1){ref-type="table"}*). Significant differences were observed among the three groups in both gender and age. The database for analysis was limited to various amounts of subject considering different aims. The detailed information is shown in *[Figure 1](#Figure1){ref-type="fig"}*.

###### 

Demographic characteristics, pathological and cytological results of subjects in different areas

  Variables                Linzhou (%)     Cixian (%)       Feicheng (%)   Total (%)       χ^2^      P^\*^
  ------------------------ --------------- ---------------- -------------- --------------- --------- ---------
  Gender                                                                                   45.343    \<0.001
  Male                     529 (32.6)      1, 367 (42.5 )   201 (37.1)     2, 097 (39.0)             
  Female                   1, 094 (67.4)   1, 850 (57.5)    341 (62.9)     3, 285 (61.0)             
  Total                    1, 623          3, 217           542            5, 382                    
  Age (year)                                                                               41.527    \<0.001
  40-49                    596 (36.7)      1, 331 (41.4)    163 (30.1)     2, 090 (38.8)             
  50-59                    678 (41.8)      1, 220 (37.9)    215 (39.7)     2, 113 (39.3)             
  60-70                    349 (21.5)      666 (20.7)       164 (30.3)     1, 179 (21.9)             
  Total                    1, 623          3, 217           542            5, 382                    
  Pathological diagnosis                                                                   227.147   \<0.001
  Normal                   733 (70.5)      980 (69.8)       264 (64.2)     1, 977 (69.2)             
  BCH                      25 (2.4)        243 (17.3)       58 (14.1)      326 (11.4)                
  LGIN                     203 (19.5)      167 (11.9)       83 (20.2)      453 (15.9)                
  HGIN                     49 (4.7)        10 (0.7)         4 (1.0)        63 (2.2)                  
  ESCC                     30 (2.9)        5 (0.4)          2 (0.5)        37 (1.3)                  
  Total                    1, 040          1, 405           411            2, 856                    
  Cytological diagnosis                                                                    142.889   \<0.001
  Normal                   1, 014 (62.5)   2, 398 (74.8)    365 (67.3)     3, 777 (70.3)             
  BCC                      255 (15.7)      443 (13.8)       110 (20.3)     808 (15.0)                
  ASCUS                    259 (16.0)      311 (9.7)        55 (10.1)      625 (11.6)                
  LISL                     69 (4.3)        46 (1.4)         11 (2.0)       126 (2.3)                 
  HISL                     11 (0.7)        7 (0.2)          1 (0.2)        19 (0.4)                  
  ESCC                     15 (0.9)        3 (0.1)          0 (0.0)        18 (0.3)                  
  Total                    1, 623          3, 208           542            5, 373                    

![Trial profiles of enrollment and screening.](cjcr-28-4-404-g001){#Figure1}

Pathologic examination {#s3-2}
----------------------

A total of 2, 856 of the 5, 382 subjects received endoscopic screening and pathological examination. The compliance was about 53.07%. The detection rate of esophageal lesions was about 31% both in different areas and in all participants. The detection rates from high to low were respectively LGIN, BCH, HGIN and ESCC, except for Linzhou, whose detection rate of BCH (2.4%) was even lower than ESCC (2.9%). The distribution of pathologic types was dissimilar significantly among the three areas (χ^2^=227.147, P\<0.001) (*[Table 1](#Table1){ref-type="table"}*).

Liquid-based cytology {#s3-3}
---------------------

All participants received balloon examination and had cytological samples, 9 of which were excluded due to slide quality. The detection rates of esophageal lesions by liquid-based cytology from high to low were respectively BCC, ASCUS, LSIL, HSIL and ESCC. While the normal was about 70% in average (3, 777/5, 373, range: 62.5% to 74.8%) and BCC was about 15% (808/5, 373, range: 13.8% to 20.3%). The distribution of cytological types was discrepant apparently among the three areas (χ^2^=142.889, P\<0.001) (*[Table 1](#Table1){ref-type="table"}*).

DNA-ICM test {#s3-4}
------------

Same as liquid-based cytology, all participants had DNA-ICM test through balloon examination and 4, 567 cases were enrolled in the analysis because of high slide quality. Absolutely normal cells were few (0.74%, 34/4, 567), and the total quantity of aneuploidy cells ascended with content of DNA ploidy increasing at first until 4.8c. Then the amount aneuploidy cells dropped sharply to about 150 and went smoothly. The number rose up again from 6.5c and reached the peak at 8c (563) eventually. Using conventional cutoff point that the content of DNA ploidy 5c and the aneuploidy cells number 3, approximately 65.16% (2, 976/4, 567) subjects were diagnosed as abnormal (*[Table 2](#Table2){ref-type="table"}*).

###### 

DNA-ICM test results in three high-risk areas in China

  Content of DNA ploidy   Number of aneuploidy cells                            
  ----------------------- ---------------------------- ---- ---- ---- ---- ---- --------
  2.0 (normal)            0                            0    0    0    0    0    34
  2.5                     4                            3    1    1    0    7    16
  3.0                     12                           0    2    1    0    1    16
  3.5                     15                           8    3    0    1    1    28
  4.0                     19                           5    6    3    2    6    41
  4.2                     61                           55   32   21   17   45   231
  4.4                     176                          89   43   25   7    23   363
  4.6                     195                          83   34   16   5    3    336
  4.8                     224                          66   23   19   4    5    341
  5.0                     144                          41   7    4    1    0    197
  5.2                     126                          33   7    2    2    0    170
  5.4                     124                          28   3    0    0    0    155
  5.6                     116                          14   5    0    0    0    135
  5.8                     89                           13   2    1    0    0    105
  6.0                     191                          20   5    3    1    0    220
  6.5                     166                          15   5    0    0    0    186
  7.0                     179                          21   6    0    0    0    206
  7.5                     301                          46   8    2    0    0    357
  8.0                     450                          84   20   6    3    0    563
  8.5                     351                          55   9    1    0    0    416
  9.0                     315                          88   18   10   4    16   451
  Total                                                                         4, 567

Distribution of DNA-ICM results based on various pathologic types {#s3-5}
-----------------------------------------------------------------

Conventional cutoff point (the content of DNA ploidy 5c and the aneuploidy cells number 3) was applied firstly to explore whether DNA-ICM test could be used for esophageal cancer primary screening. As shown in *[Table 3](#Table3){ref-type="table"}*, with increasing pathologic grades, the abnormal group accounted for larger percentage (χ^2^=18.016, P\<0.001). In esophageal cancer subjects, up to 96% cases could be found out by DNA-ICM test.

###### 

Distribution of DNA-ICM results based on various pathologic types

  DNA-ICM diagnosis   n (%)                                                             
  ------------------- --------------- ------------ ------------ ----------- ----------- ---------------
  \<5, 003            577 (33.5)      87 (35.7)    93 (24.6)    8 (15.4)    1 (4.0)     766 (31.7)
  5, 003              1, 144 (66.5)   157 (64.3)   285 (75.4)   44 (84.6)   24 (96.0)   1, 654 (68.3)
  Total               1, 721          244          378          52          25          2, 420

Cutoff points of DNA-ICM based on dissimilar pathologic types {#s3-6}
-------------------------------------------------------------

ROC curves were employed to illustrate cutoff point for DNA-ICM test. The area under the curves (AUCs) was 0.584, 0.703 and 0.811 respectively for pathologic types of LGIN, HGIN and ESCC. We further applied Youden's index to confirm the cutoff point for each pathologic type. The cutoff points lay on the largest Youden's index point of each ROC curve, which were 5, 802 for LGIN, 5, 803 for HGIN and 8, 002 for ESCC, namely, the content of DNA ploidy 5.8c and the aneuploidy cells number 3 were the appropriate cutoff points for HGIN, and the explanation for 5, 802 and 8, 002 was by analogy (*[Table 4](#Table4){ref-type="table"}*, *[Figure 2](#Figure2){ref-type="fig"}*).

###### 

Cutoff points of DNA-ICM based on different pathologic types

  Pathologic types   AUC     95% CI of AUC   P          Cutoff point   SE (%)   SP (%)   Youden\'s index
  ------------------ ------- --------------- ---------- -------------- -------- -------- -----------------
  LGIN               0.584   0.555-0.613     P\<0.001   5, 802         67.0     46.7     0.137
  HGIN               0.703   0.643-0.762     P\<0.001   5, 803         83.1     45.3     0.284
  ESCC               0.811   0.728-0.895     P\<0.001   8, 002         68.0     76.9     0.449

![ROC curves on the basis of various pathologic types. (A) LGIN; (B) HGIN; (C) ESCC.](cjcr-28-4-404-g002){#Figure2}

Screening ability of liquid-based cytology and DNA-ICM test based on different pathologic types {#s3-7}
-----------------------------------------------------------------------------------------------

When focusing on each kind of pathology results, the SE declined and SP rose in turn with higher grade of cytological or DNA-ICM classifications. In ≥HGIN, the SE dropped from 83.1% to 50.6%, while SP grew from 45.0% to 77.3%, when the result of DNA-ICM test changed from 5, 802 to 8, 002. What's more, in each classification of liquid-based cytology or DNA-ICM, the SE increased significantly and the SP decreased smoothly when higher grade of pathologic types were used as classification criterion. With the classification of DNA-ICM being 5, 803, the SE went from 66.4% up to 96.0% when the pathologic classification criterion changed from ≥LGIN to ESCC. More importantly, the SE of DNA-ICM test was always higher than that of liquid-based cytology (*[Table 5](#Table5){ref-type="table"}*).

###### 

Screening ability of liquid-based cytology, DNA-ICM test and the combination (%)

  Methods                                    ≥LGIN                                 ≥HGIN                                 ESCC                                                                                                                                                                       
  ----------------------- ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ---------------
  Liquid-based cytology   ≥ASCUS             32.0 (30.3-33.7)   85.0 (83.7-86.3)   83.9 (82.6-85.2)   33.8 (32.1-35.5)                      59.0 (57.2-60.8)   83.2 (81.8-84.6)   98.2 (97.7-98.7)   11.3 (10.1-12.5)                      70.3 (68.6-72.0)   82.4 (81.0-83.8)   99.5 (99.2-99.8)   5.0 (4.0-5.8)
  ≥LSIL                   12.8 (11.6-14.0)   97.7 (97.2-98.2)   82.4 (81.0-83.8)   57.7 (55.9-59.5)                      38.0 (36.2-39.8)   96.9 (96.3-97.5)   97.7 (97.2-98.2)   30.9 (29.2-32.6)                      56.8 (55.0-58.6)   96.4 (95.7-97.1)   99.4 (99.1-99.7)   17.1 (15.7-18.5)   
  ≥HSIL                   4.7 (3.9-5.5)      99.7 (99.5-99.9)   81.3 (79.9-82.7)   76.5 (79.9-78.1)                      26.0 (24.4-27.6)   99.7 (99.5-99.9)   97.4 (96.8-98.0)   76.5 (74.9-78.1)                      51.4 (49.6-53.2)   99.5 (99.2-99.8)   99.4 (99.1-99.7)   55.9 (54.1-57.7)   
  ESCC                    2.7 (2.1-3.3)      99.9 (99.8-100)    81.0 (79.6-82.4)   83.3 (81.9-84.7)                      15.0 (13.7-16.3)   99.9 (99.8-100)    97.0 (96.4-97.6)   83.3 (81.9-84.7)                      35.1 (33.3-36.9)   99.8 (99.6-100)    99.2 (98.9-99.5)   72.2 (70.6-73.8)   
  DNA-ICM                 ≥5, 802            67.0 (65.1-68.9)   46.7 (44.7-48.7)   85.9 (84.5-87.3)   67.0 (65.1-68.9)                      83.1 (81.6-84.6)   45.0 (43.0-47.0)   98.8 (98.4-99.2)   4.7 (3.9-5.5)                         96.0 (95.2-96.8)   44.5 (42.5-46.5)   99.9 (99.8-100)    1.8 (1.3-2.3)
  ≥5, 803                 66.4 (64.5-68.3)   46.9 (44.9-48.9)   85.8 (84.4-87.2)   22.4 (20.7-24.1)                      83.1 (81.6-84.6)   45.3 (43.3-47.3)   98.8 (98.4-99.2)   3.8 (3.0-4.6)                         96.0 (95.2-96.8)   44.8 (42.8-46.8)   99.9 (99.8-100)    1.8 (1.3-2.3)      
  ≥8, 002                 29.9 (28.1-31.7)   77.9 (76.2-79.6)   82.8 (81.3-84.3)   23.9 (22.2-25.6)                      50.6 (48.6-52.6)   77.3 (75.6-79.0)   97.9 (97.3-98.5)   6.8 (5.8-7.8)                         68.0 (66.1-69.9)   76.9 (75.2-78.6)   99.6 (99.3-99.9)   3.0 (2.3-3.7)      
  Combination                                72.1 (70.3-73.9)   43.3 (41.3-45.3)   87.0 (85.7-88.3)   22.8 (21.1-24.5)                      85.7 (84.3-87.1)   41.3 (39.3-43.3)   98.9 (98.5-99.3)   4.6 (3.8-5.4)                         96.0 (95.2-96.8)   40.8 (38.8-42.8)   99.9 (99.8-100)    1.7 (1.2-2.2)

SE and SP of combination of liquid-based cytology and DNA-ICM {#s3-8}
-------------------------------------------------------------

In this study, ≥5, 803 of DNA-ICM test and ASCUS of liquid-based cytology were taken as threshold values for combination of the two methods to explore a better primary screening method. As shown in *[Table 5](#Table5){ref-type="table"}*, the SE for HGIN was 85.7%, which was higher than both of the two methods alone. The same also happened in other pathologic classification criterions.

Discussion {#s4}
==========

Marked achievements had been made in esophageal cancer with endoscopic screening in China ([@b12]). Although high SE and SP had been proved ([@b10], [@b11]), some limitations, such as the relatively unacceptable cost and the necessity for experienced pathologists and endoscopic physicians, however, restricted the extension of endoscopic screening in China, especially in rural areas, where the most high-risk areas of esophageal cancer located. Therefore, the demand for some economic and easier primary screening methods before endoscopic screening with applicable SE emerged for asymptomatic population, which could not only narrow the population for endoscopic screening, but also enhance the screening efficiency, and thereby make it possible to promote endoscopic screening.

These days, an alternative method for examination of precancer lesions is DNA-ICM test. It is accepted worldwide, as a successful method in order to screen for epithelial dysplasia *in situ* or invasive carcinomas of the uteri cervix ([@b16]). The limited studies of DNA-ICM test on esophageal cancer focused on prognosis. Our team once discovered that DNA-ICM was suitable for esophageal cancer primary screening. But the cutoff point in that research was the conventional one and the sample size was deficient. To this end, based on the population cohort established in Lizhou, Cixian and Feicheng from 2008 to 2011, this study discussed the probability of DNA-ICM test for esophageal cancer screening and meanwhile explored the cutoff point for DNA-ICM test, with the gold standard of endoscopic biopsy examination with Lugol's iodine staining. We further compared the method with liquid-based cytology and combined the two to investigate a primary screening approach for esophageal cancer and precancerous lesions. Besides, the content of DNA ploidy and the aneuploidy cells were united as one index to avoid the multiple biases resulted from various indexes.

The screening significance of DNA-ICM test in esophageal cancer is still controversial since few attempts have been made on this. Using the conventional classification of content of DNA ploidy 5c and the number of aneuploidy cells 3, we validated our previous study with a larger sample size. The data showed a strong correlation between DNA aneuploidy and increased risk of incidence (χ^2^=18.016, P\<0.001), which was in agreement with the previous results ([@b17]) and proved it is possible that the DNA-ICM could be used for esophageal cancer screening.

No proper cutoff value was specially established for esophageal cancer screening before. In this study, LGIN, HGIN and ESCC were set respectively as the thresholds for golden standard of pathological examination (*[Table 4](#Table4){ref-type="table"}*). Three ROC curves were then depicted based on different thresholds and the cutoff points were 5, 802, 5, 803 and 8, 002 for LGIN, HGIN and ESCC, which were chosen from the ROC curves where the Youden's index was the highest. The cutoff point 5, 803, that was, the content of DNA ploidy 5.8c and the aneuploidy cells number 3, was ultimately defined as cutoff point for DNA-ICM test in our study on account of the following explanations. To begin with, the SE was too low for a primary screening method (22.9% for LGIN, 50.6% for ≥HGIN and 68.0% for ESCC), if 8, 002 was applied as the cutoff point. Secondly, the SE of 5, 802 and 5, 803 were practically the same no matter which pathologic threshold was and the SP of 5, 803 was a little higher than that of 5, 802. More importantly, it was the patients with pathologic results of HGIN that we cared about more, as patients diagnosed with HGIN or worse had little opportunity to reverse to LGIN or normal and treatment must be given to prolong their life-span and improve their living quality, which was the basic purpose for cancer screening ([@b18]).

The aim of primary screening was to find out suspicious cases as many as possible before endoscopic screening, and so the method with high SE was preferable. We compared the DNA-ICM test with liquid-based cytology and then combined the two methods to get the best way for esophageal cancer screening. As shown in *[Table 5](#Table5){ref-type="table"}*, the SE of DNA-ICM test with threshold of ≥5, 803 (≥LGIN 66.4%, ≥HGIN 83.1% and ESCC 96.0%) was much higher than that of liquid-based cytology with threshold of ≥ASCUS (≥LGIN 32.0%, ≥HGIN 59.0% and ESCC 70.3%), which highlighted that the DNA-ICM was prior to liquid-based cytology for primary screening. We then united the two methods in the hope of achieving high SE, but the results were the opposite. The SE was improved little (≥LGIN 72.1%, ≥HGIN 85.7% and ESCC 96.0%), indicating that the combination was no better than DNA-ICM alone and was not suitable for screening ESCC and precancerous lesions, which was in accordance with our previous study.

Several superiorities make the DNA-ICM test a reasonable primary screening method. On the one hand, DNA-ICM test is easier to perform. Training for cytologists, endoscopists and pathologists for liquid-based cytology test or endoscopic screening is arduous and time-consuming, which restricts the application of the two methods to the entire population. However, for DNA-ICM test, a technician could work independently after 3 weeks of training, and 90% of slides could be diagnosed in one minute. On the other hand, cytological diagnosis largely depends on the experiences of cytologists, but DNA-ICM is more objective as it is read by computer ([@b19]). This might be a justifiable reason for various sensitivities of cancer screening. Our study also has some limitations. The quality of DNA-ICM specimens is supposed to be enhanced, since a total of 5, 382 subjects participated in DNA-ICM test, but only 4, 567 (84.86%) specimens were employed for analysis. Only when the quality is improved, will the method be possible to spread nationwide.

Conclusions {#s5}
===========

The cutoff point of DNA-ICM for primary screening of esophageal cancer was 5, 803, that is, the content of DNA ploidy 5.8c and the aneuploidy cells number 3. DNA-ICM test alone as a primary screening method possesses potential benefits in detecting esophageal cancer and its precursors with significantly high SE than liquid-based cytology.
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